Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
Executive Summary
The latest US drug development news and highlights from our Performance Tracker.
You may also be interested in...
AbbVie Data Show Skyrizi Tops IL-17 Competitors In Skin Clearance
Skyrizi showed better skin-clearance results than Cosentyx or Taltz in a 52-week study of patients who had suboptimal results on the latter two drugs.
Keeping Track: FDA Clears Motegrity And Second Herceptin Biosimilar, But Rebuffs SpecGx's Oxycodone
The latest drug development news and highlights from our US FDA Performance Tracker.
As AbbVie's Risankizumab Looms, Sun Pushes To 'Maximize Time' Of Ilumya
Sun says that it is "excited" with Ilumya’ s initial launch uptake in the crowded US psoriasis segment, but is pushing ahead with "speedy execution" of plans for the product before the potential arrival of new rivals such as AbbVie’s same-class therapy risankizumab.